Results 251 to 260 of about 91,213 (314)

GALNT9 enrichment attenuates MPP+-induced cytotoxicity by ameliorating protein aggregations containing α-synuclein and mitochondrial dysfunction [PDF]

Yuanwen Peng, Jun Liu, Lili Sun, Qiuying Zheng, Can Cao, Wenyong Ding, Shufeng Yang, Li Ma, Wenli Zhang   +8 more
openalex   +1 more source

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay

Movement Disorders, EarlyView.
Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker, Jacopo Pasquini, Seung Ho Choi, David‐Erick Lafontant, Seyed‐Mohammad Fereshtehnejad, Yashar Zeighami, Piergiorgio Grillo, Giulietta M. Riboldi, Houman Azizi, Roqaie Moqadam, Un Jung Kang, Kelly N.H. Nudelman, Andrew Siderowf, Caroline M. Tanner, Thomas F. Tropea, Tatiana Foroud, Lana M. Chahine, Brit Mollenhauer, Kalpana M. Merchant, Douglas Galasko, Christopher S. Coffey, Roseanne D. Dobkin, Ethan G. Brown, Roy N. Alcalay, Daniel Weintraub, Kenneth Marek, Tanya Simuni, Paulina Gonzalez‐Latapi, Nicola Pavese, Kathleen L. Poston, the Parkinson's Progression Markers Initiative   +30 more
wiley   +1 more source

Oxidative modification of methionine residue in α-synuclein by dopamine induces cellular vulnerability, oligomerization and secretion of α-synuclein. [PDF]

J Clin Biochem Nutr
Kato Y, Kanatani M, Adachi T, Nagamine H, Horikoshi Y, Nakaso K.   +5 more
europepmc   +1 more source

Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment

Movement Disorders, EarlyView.
Abstract Background Autonomic dysfunction is a known contributor to cognitive impairment in Parkinson's disease (PD), but its impact during prodromal stage is unknown. Objective The aim was to determine whether early autonomic burden predicts incident cognitive impairment in prodromal PD.
A. Enrique Martinez‐Nunez, Kelly A. Mills, Joseph Seemiller, Christopher B. Morrow, Gregory M. Pontone, Abhimanyu Mahajan   +5 more
wiley   +1 more source

Identification of KHS-101 as a Transcription Factor EB Activator to Promote α-Synuclein Degradation. [PDF]

Int J Mol Sci
Zhu H, Ren A, Li T, Zhou T, Li A, Pan X, Chen L, Chen J.   +7 more
europepmc   +1 more source

Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers

Movement Disorders, EarlyView.
Abstract Background GBA1 encodes the lysosomal enzyme glucocerebrosidase, with key substrates that include glucosylceramide and glucosylsphingosine. The E365K variant is the most common variant in GBA1 that is associated with Parkinson's disease (PD) but is not associated with Gaucher disease.
Julian Agin‐Liebes, Alexander Haimovich, Rachel Griep, Nathan Galen Hatcher, Lihang Yao, Cheryl Waters, Shalini Padmanabhan, Roy N. Alcalay   +7 more
wiley   +1 more source

ATP Hydrolysis by α-Synuclein Amyloids is Mediated by Enclosing β-Strand. [PDF]

Adv Sci (Weinh)
Frey L, Buratti FA, Horvath I, Parate S, Kumar R, Riek R, Wittung-Stafshede P.   +6 more
europepmc   +1 more source

Challenges and Opportunities in State‐of‐the‐Art Proteomics Analysis for Biomarker Development From Plasma Extracellular Vesicles

PROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐bound particles secreted by cells, playing crucial roles in intercellular communication. The composition of EVs can undergo changes in response to stress and disease conditions, making them excellent biomarker candidates.
Panshak P. Dakup, Ivo Diaz Ludovico, Youngki You, Chaitra Rao, Javier Flores, Lisa M. Bramer, Marian Rewers, Bobbie‐Jo M. Webb‐Robertson, Thomas O. Metz, Raghavendra G. Mirmira, Emily K. Sims, Ernesto S. Nakayasu   +11 more
wiley   +1 more source

Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains

PROTEOMICS, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and pathological protein aggregation. Comprehensive quantitative proteomics of brain tissues from AD patients is critical for pursuing a better understanding of the molecular mechanisms that drive AD progression.
Mehrdad Falamarzi Askarani, Fei Fang, Scott E. Counts, Liangliang Sun   +3 more
wiley   +1 more source

Synaptic Vesicle Disruption in Parkinson's Disease: Dual Roles of α-Synuclein and Emerging Therapeutic Targets. [PDF]

Brain Sci
Treviño M, Guerra-Crespo M, Padilla-Godínez FJ, Ortega-Robles E, Arias-Carrión O.   +4 more
europepmc   +1 more source